Sanofi SA (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 233   

Articles published

SNY 46.39 -0.42 (-0.90%)
price chart
Sanofi SA (SNY) Stock On A Decline Since Ousting Of CEO Chris Viehbacher
Shares of Sanofi SA (ADR) (SNY) continue their downward journey since Chris Viehbacher was ousted from his position as CEO late October by the company's board of directors in the coup led by Chairman Serge Weinberg.
Related articles »  
Sanofi (SNY) Expects $37.6 Billion Revenues From New Drugs
Sanofi SA (ADR) (NYSE:SNY), which has recently been in the limelight for the much publicized ousting of its former CEO Christopher Viehbacher, expressed confidence in its drug pipeline in a statement today.
Related articles »  
Stock to Watch: Sanofi SA (ADR) (NYSE:SNY)
[PRNewswire] Sanofi SA (ADR) (NYSE:SNY) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental biologics license application (sBLA) for Fluzone Intradermal Quadrivalent vaccine.
Traders Alert-Sanofi (SNY), Zurich (ZURVY), Keryx (KERX), PAGNIE (CFRUY)  Techsonian (press release)
Related articles »  
Buzz Stocks: Orbital Sciences Corp, Sanofi SA (ADR), and American Realty ...
Futures are little changed this morning, as investors await this afternoon's policy statement from the Federal Open Market Committee (FOMC).
Deutsche Bank Downgrades Sanofi SA  Benzinga
Sanofi SA Downgraded by Barclays (SNY)  sleekmoney
Related articles »  
Investor Watch: Fred's, Inc. (NASDAQ:FRED), Sanofi SA (ADR) (NYSE:SNY ...
Sanofi SA (ADR) (NYSE:SNY) was initiated with outperform rating coverage from analysts at Exane BNP Paribas which is being seen as a huge positive for the stock.
Related articles »  
Is Now A Good Time To Sell Sanofi SA (ADR) (NYSE:SNY), 2 Others? � National ...
Sanofi SA (ADR) (NYSE:SNY) plunged 5.93% to new low on heavy volume as Chief Executive Christopher Viehbacher departed after the board voted to oust him.
Stocks Alert: National Bank of Greece (ADR)(NYSE:NBG), Sanofi SA (ADR ...  Market News Call
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Sanofi, Regeneron Release Data For Sinusitis Drug
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) have released positive data from a Phase IIa study for their investigational drug dupilumab.
Related articles »  
Dengue Outbreak Hits China; Sanofi In Lead For Cure
(ADR) (FUJIY) to step forward with their respective anti-Ebola treatment therapies. The Ebola outbreak has claimed about 3,500 lives as of October 8. This might have brought out the pharmaceutical industry's human side.
Related articles »  
Sanofi Responds To Bribery Allegations
Sanofi SA (ADR) (SNY) responded to allegations of bribery activity in the Middle East and Africa late Monday, stating that it has notified relevant US authorities about the issue and is conducting a private investigation into the matter.
Related articles »